Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question

PURPOSE: Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversial issue. RESULTS: Serum testosterone in CRPC patients has a positive prognostic r...

Descripción completa

Detalles Bibliográficos
Autores principales: Caramella, Irene, Dalla Volta, Alberto, Bergamini, Marco, Cosentini, Deborah, Valcamonico, Francesca, Berruti, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637055/
https://www.ncbi.nlm.nih.gov/pubmed/35986139
http://dx.doi.org/10.1007/s12020-022-03166-w
_version_ 1784825090998796288
author Caramella, Irene
Dalla Volta, Alberto
Bergamini, Marco
Cosentini, Deborah
Valcamonico, Francesca
Berruti, Alfredo
author_facet Caramella, Irene
Dalla Volta, Alberto
Bergamini, Marco
Cosentini, Deborah
Valcamonico, Francesca
Berruti, Alfredo
author_sort Caramella, Irene
collection PubMed
description PURPOSE: Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversial issue. RESULTS: Serum testosterone in CRPC patients has a positive prognostic role and increasing testosterone levels after androgen deprivation therapy (ADT) withdrawal or testosterone supplementation, as part of a bipolar androgen therapy (BAT) strategy, has been shown to potentially restore sensitivity to previous lines of NGHAs. CONCLUSION: These data suggest that maintenance of ADT in CRPC patients receiving further lines of treatment, as recommended by current international guidelines, could be questionable. Conversely, testosterone supplementation aimed to re-sensitize CRPC to further hormonal manipulation is a strategy worth to be explored in future clinical trials.
format Online
Article
Text
id pubmed-9637055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96370552022-11-07 Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question Caramella, Irene Dalla Volta, Alberto Bergamini, Marco Cosentini, Deborah Valcamonico, Francesca Berruti, Alfredo Endocrine Viewpoint PURPOSE: Whether or not androgen receptor (AR) axis could still be targetable in castration resistant prostate cancer (CRPC) patients with disease progression to next generation hormonal agents (NGHAs) is a controversial issue. RESULTS: Serum testosterone in CRPC patients has a positive prognostic role and increasing testosterone levels after androgen deprivation therapy (ADT) withdrawal or testosterone supplementation, as part of a bipolar androgen therapy (BAT) strategy, has been shown to potentially restore sensitivity to previous lines of NGHAs. CONCLUSION: These data suggest that maintenance of ADT in CRPC patients receiving further lines of treatment, as recommended by current international guidelines, could be questionable. Conversely, testosterone supplementation aimed to re-sensitize CRPC to further hormonal manipulation is a strategy worth to be explored in future clinical trials. Springer US 2022-08-20 2022 /pmc/articles/PMC9637055/ /pubmed/35986139 http://dx.doi.org/10.1007/s12020-022-03166-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Viewpoint
Caramella, Irene
Dalla Volta, Alberto
Bergamini, Marco
Cosentini, Deborah
Valcamonico, Francesca
Berruti, Alfredo
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
title Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
title_full Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
title_fullStr Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
title_full_unstemmed Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
title_short Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
title_sort maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
topic Viewpoint
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637055/
https://www.ncbi.nlm.nih.gov/pubmed/35986139
http://dx.doi.org/10.1007/s12020-022-03166-w
work_keys_str_mv AT caramellairene maintenanceofandrogendeprivationtherapyortestosteronesupplementationinthemanagementofcastrationresistantprostatecancerthatisthequestion
AT dallavoltaalberto maintenanceofandrogendeprivationtherapyortestosteronesupplementationinthemanagementofcastrationresistantprostatecancerthatisthequestion
AT bergaminimarco maintenanceofandrogendeprivationtherapyortestosteronesupplementationinthemanagementofcastrationresistantprostatecancerthatisthequestion
AT cosentinideborah maintenanceofandrogendeprivationtherapyortestosteronesupplementationinthemanagementofcastrationresistantprostatecancerthatisthequestion
AT valcamonicofrancesca maintenanceofandrogendeprivationtherapyortestosteronesupplementationinthemanagementofcastrationresistantprostatecancerthatisthequestion
AT berrutialfredo maintenanceofandrogendeprivationtherapyortestosteronesupplementationinthemanagementofcastrationresistantprostatecancerthatisthequestion

Ejemplares similares